Top View
- Efalizumab in the Treatment of Psoriasis
- Biological Agents Targeting Beyond TNF-Alpha
- Recent Biotherapies and Infections
- International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
- (INN) for Biological and Biotechnological Substances
- FDA Approved Indications1-3
- Extended Efalizumab for Psoriasis Well Tolerated
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep
- (12) United States Patent (10) Patent No.: US 9,683,047 B2 Smith Et Al
- Criteria for Non Formulary Use Of
- When and How to Switch Psoriasis Patients from Anti-TNF Therapy
- Aseptic Meningitis-Retention Syndrome Associated with Tocilizumab in a Patient with Idiopathic Multicentric Castleman Disease
- Biological Agents Targeting Beyond TNF-Alpha
- Ustekinumab Improves Nail Disease in Patients with Moderate-To-Severe Psoriasis: Results from PHOENIX 1 P
- Raptiva Withdrawal
- Customs Tariff - Schedule Xxi - 1
- Exploring Off-Label Use of Biologics for Dermatologic Indications
- Drug Class Review Targeted Immune Modulators
- Assessment Report
- A Review of Complications of Biologic Therapy for Psoriasis Therapeutic Success Requires Clinicians to Understand Emerging and Established Safety Concerns
- Omalizumab for the Treatment of Atopic Dermatitis
- Tocilizumab), Human Igg1 Antibody
- Specialty Drug List
- Dorset Medicines Advisory Group
- Successful Treatment of Alopecia Universalis with Alefacept: a Case Report and Review of the Literature
- Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
- Systematic Review of Chimpanzee Use in Monoclonal Antibody Research and Drug Development: 1981-2010
- Raptiva, INN-Efalizumab
- Immunomodulatory Treatment for the Intractable Paediatric Epilepsies Luis E
- Tocilizumab) in Neuromyelitis Optica and NMO Spectrum Disorders
- Efalizumab for Patients with Moderate to Severe Plaque Psoriasis a Randomized Controlled Trial
- Overview of MS Management
- Thalidomide - Wikipedia, the Free Encyclopedia
- Certolizumab Pegol (Cimzia) for Chronic Plaque Psoriasis in Adults NIHRIO (HSRIC) ID: 2406 NICE ID: 9112
- The Future of Biological Therapies Richard B
- JC Virus Seroprevalence and Jcvab Index in Polish Multiple Sclerosis Patients Treated with Immunomodulating Or Immunosuppressive Therapies
- Clinical Development Strategies and Regulatory Outcomes of FDA Approved Biological License Applications – Therapeutic Domain Considerations
- Stelara (Ustekinumab) Injection
- International Nonproprietary Names (INN) for Biological and Biotechnological Substances
- 5 Efalizumab: Antibody Characteristics, Mode of Action and Preclinical Development S.Jahn,K.Schmitt-Rau
- Xolair (Omalizumab) AHM
- Raptiva, INN-Efalizumab
- Natalizumab (Tysabri®) Algorithm in Multiple Sclerosis
- Certolizumab Pegol for Treating Moderate to Severe Plaque Psoriasis [ID1232]
- Hypersensitivity Reactions to Biologics (Part I)